Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product registrations
Highlights- TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets.
- The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™.
- TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026.
- Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity.
- Once required registrations are completed, TempraMed products are expected to be available through distribution relationships covering seven Latin American countries representing a substantial majority of the region's population.
- TempraMed expects to raise up toC$1,000,000 through non-brokered private placement of Units
Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("
TempraMed" or the "
Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has entered into an amendment dated September 23, 2026 (the "
Amended Agreement") to its definitive exclusive distribution agreement with TEM Consulting International S.A. ("
TEM"), expanding the relationship beyond Panama into additional Latin American markets and adding VIVI Med™ to the distribution framework. In connection with the amendment, TempraMed has received an additional commercial order from TEM, which the Company expects to fulfill by the end of September 2026. The additional order follows the previously announced transition of the parties' relationship from a non-binding LOI into a definitive exclusive distribution agreement for Panama and reflects TEM's continued market-development activity for TempraMed products across the region. The amendment extends the distribution territory to include Argentina, Venezuela, Colombia and Costa Rica, in addition to TEM's existing Panama relationship. Separately, TempraMed has previously announced distribution initiatives in Brazil and Mexico. Once required registrations and launch activities are completed in the applicable markets, TempraMed products are expected to be available through distribution relationships covering seven Latin American countries: Panama, Argentina, Venezuela, Colombia, Costa Rica, Mexico and Brazil.
Expanded Commercial Framework The Amended Agreement includes an initial commercial extended-territory order across the added countries. Units under the initial extended-territory order may consist of any combination of VIVI Cap™, VIVI Epi™ and VIVI Med™, at TEM's election. The amendment also adds VIVI Med™ to the products covered under the agreement. VIVI Med™ is designed to expand TempraMed's temperature-protection platform beyond standard insulin pens to include vials, biologics, and other temperature-sensitive medications and supplies, supporting the Company's broader portfolio strategy in Latin America. TEM will be responsible, at its sole cost, for obtaining required governmental licenses, registrations, approvals, importation authorizations, customs clearance, labeling compliance and other regulatory or commercial requirements necessary to commercialize the products in each applicable country.
Seven-Country Latin American Coverage Opportunity With the existing Panama agreement, the expanded territory under the Amended Agreement, and TempraMed's separate Brazil and Mexico initiatives, the Company is building a distribution footprint that is expected to cover seven countries in South and Central America once products are registered in each applicable market. Management believes this represents an important regional scale opportunity. Based on World Bank population data, Latin America and the Caribbean had approximately 666.6 million people in 2025. The seven countries covered by TempraMed's current and contemplated distribution initiatives collectively represent more than 70% of that regional population. Latin America is an important growth region for TempraMed because many patients use temperature-sensitive medications in hot climates and in settings where daily travel, pharmacy-to-home transport, outdoor work, power interruptions and fragmented healthcare access can increase the risk of medication temperature exposure. TempraMed's product portfolio is designed to provide practical, passive, reusable protection for insulin, GLP-1 therapies, biologics, epinephrine auto-injectors, vials and other temperature-sensitive medications without batteries, charging or external power. The expanded relationship with TEM supports TempraMed's strategy to...
